National Bank of Canada’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

National Bank of Canada’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-461	Closed	-$1K	–	3000
2022 Q2	$1K	Sell	461 -2	-0.4%	-$3	﹤0.01%	2759
2022 Q1	$2K	Buy	463 +64	+16%	+$403	﹤0.01%	2751
2021 Q4	$2K	Buy	+399	New	+$3.39K	﹤0.01%	2718

Other funds holding EVFM

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

National Bank of Canada's EVFM Position: Q3 2022 in Review

National Bank of Canada sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 461 shares — an estimated $1K sold.

National Bank of Canada first reported a position in EVFM in Q4 2021 and held it in 3 quarters. The position peaked at $2K in Q1 2022. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

National Bank of Canada reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
National Bank of Canada sold 461 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $1K.
National Bank of Canada first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
National Bank of Canada's Evofem Biosciences, Inc. Common Stock position peaked at $2K in Q1 2022.
8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on National Bank of Canada's 13F filing for Q3 2022, filed 13 Oct 2022.